Citizens Reiterates Rating on Crinetics Pharmaceuticals, Inc. $CRNX
Key Points
- Citizens now rates Crinetics Pharmaceuticals, Inc. ($CRNX) "buy" with a $95 target.
- Citizens's $95 price target implies 170.50% upside from Crinetics Pharmaceuticals, Inc.'s ($CRNX) current $35.12 share price.
- The Street's average $CRNX price target is $85.50 (Hold).
- $CRNX last traded around $35.12.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Citizens reiterated its rating on Crinetics Pharmaceuticals, Inc. ($CRNX) to a "buy" rating in a recent research note and set a price target of $95, a 170.50% upside from the current price.
Crinetics Pharmaceuticals, Inc. Stock Down 58.6%
Shares of Crinetics Pharmaceuticals, Inc. ($CRNX) traded around $35.12 on Saturday, down 58.6% for the day.
Crinetics Pharmaceuticals, Inc. Earnings
Analysts Set New Price Targets
About Crinetics Pharmaceuticals, Inc.
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in a Phase 3 clinical trial for the treatment of acromegaly and carcinoid syndrome associated with neuroendocrine tumors. It is also developing Atumelnant, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and cushing's disease; and CRN09682, a nonpeptide drug conjugate for SST2 positive solid tumors. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease; and SST3 Agonist program for the treatment of polycystic kidney disease, as well as Oral GLP-1 and Oral GIP nonpeptides for the treatment of obesity. The company has an agreement with Sanwa Kagaku Kenkyusho Co., Ltd to develop and commercialize Paltusotine in Japan, and Cellular Longevity, Inc. to develop and commercialize CRN01941, a somatostatin receptor type 2 agonist. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Get Crinetics Pharmaceuticals, Inc. alerts
New 13F filings, insider trades, and analyst moves on $CRNX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.